Tolerability profile of zolmitriptan (Zomig™ 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist

Cephalalgia

Volumn 17, Issue 18_suppl, 1997, Pages 41-52

  Edmeads, J G ^a   Millson, D S ^b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b ASTRAZENECA   (United Kingdom)

Author keywords

5HT1B 1D receptor agonists; Migraine; tolerability; zolmitriptan

Indexed keywords

PLACEBO; SUMATRIPTAN; ZOLMITRIPTAN;

ADULT; AGED; ARTICLE; ASTHENIA; BURNING SENSATION; CHEST HEAVINESS; CHEST PRESSURE; CHEST TIGHTNESS; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPERTENSION; KIDNEY DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NAUSEA; NECK PAIN; OUTCOME ASSESSMENT; PARESTHESIA; PSYCHOMETRY; RECOMMENDED DRUG DOSE; SOMNOLENCE; THORAX DISEASE; THORAX PAIN; URINALYSIS; XEROSTOMIA; DROWSINESS; RISK BENEFIT ANALYSIS; VERTIGO;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; CARDIOVASCULAR SYSTEM; CHILD; HUMANS; INCIDENCE; MIDDLE AGED; OXAZOLES; OXAZOLIDINONES; REFERENCE VALUES; SEROTONIN AGONISTS; SUMATRIPTAN; TRYPTAMINES;

EID: 0030773549     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102497017S1806     Document Type: Article

References (24)

1. Silberstein SD., Migraine symptoms: survey of 500 self-reported migraineurs. Headache 1995; 35; 286 (Abs 4)
2. Göbel H, Petersen-Braun M, Heinze A., Which properties do patients expect of new and improved drugs in the treatment of primary headache disorders? Front Headache Res 1997; 6: 93-8
3. 1D agonist drugs: selectively targeting additional sites of action. Eur Neurol 1996; 36 Suppl 2: 13-18
4. Seaber E, On N, Phillips S, Churchus R, Posner J, Rolan P., The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male subjects. Br J Clin Pharmacol 1996; 41: 141-7
5. Dixon R, Warrander A., The clinical pharmacokinetics of zolmitriptan. Cephalalgia 1997; 17 Suppl 18: 15-20
6. 1B/1D agonist for migraine. Cephalalgia 1997; 17 Suppl 18: 4-14
7. Lance JW., Current concepts of migraine pathogenesis. Neurology 1993; 43 Suppl 3: S11-15
8. 1B/1D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic targets in migraine? Pain 1996; 67: 355-59
9. rd European Headache Conference 1996: 14-15
10. 1B/1D agonist: an overview of efficacy. Cephalalgia 1997; 17 Suppl 18: 28-40
11. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 Suppl 7: 1-96
12. Dowson AJ., 311C90: patient profiles and typical case histories of migraine management. Neurology 1997; 48 Suppl 3: S29-33
13. Simmons VE, Blakeborough P., The safety profile of sumatriptan. Review of Contemporary Pharmacotherapy 1994; 5: 319-28
14. Visser WH, Terwindt GM, Reines SA, Jiang K, Lines CR, Ferrari MD, for the Dutch/US Rizatriptan Study Group. Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Arch Neurol 1996; 53: 1132-7
15. Visser WH, Jaspers NMWH, de Vriend RHM, Ferrari M., Chest symptoms after sumatriptan: a two-year clinical practice review of 735 consecutive migraine patients. Cephalalgia 1996; 16: 554-9
16. 1D) agonists and other agents in acute migraine. Neurol Clin 1997; 15: 61-83
17. 1D agonist, prevent migraine headache when taken during an aura? Eur Neurol 1996; 36 Suppl 2: 28-31
18. 1D agonist for the treatment of migraine, lorazepam and placebo on psychometric task performance in healthy volunteers. Headache 1995; 35: 304 (Abs 25)
19. Dixon R, Gillotin C, Gibbens M, Posner I, Peck RW., The pharmacokinetics and effects on blood pressure of multiple doses of the novel antimigraine drug zolmitriptan (311C90) in healthy volunteers. Br J Clin Pharmacol 1997; 43: 273-81
20. Smith DA, Phillips L, Fleck RJ, Lasseter KC, Shamblen S, Adam KD., 311C90 in normotensive and mild to moderate hypertensive volunteers: a pharmacodynamic and pharmacokinetic comparison. Cephalalgia 1995; 15: 219 (Abs P17)
21. nd Congress of the European Federation of Neurological Sciences, Rome, 30 Oct-3 Nov 1996
22. Ferrari MD., 311C90: increasing the options for therapy with effective acute antimigraine 5HT1B/1D agonists. Neurology 1997; 48 Suppl 3: S21-4
23. Kaube H, Hoskin KL, Goadsby PJ., Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br J Pharmacol 1993; 109: 788-92
24. ™. Cephalalgia 1997; 17 Suppl 18: 21-7